Imatinib Mesylate Tablet, Film Coated
Product Images NDC 68001-490

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 68001-490). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

400mg Label

Imatinib Mesylate is a medicine that comes in the form of a tablet, with each containing 400 mg of imatinib free base. It is manufactured by Hras and BluePoint Laboratories in India under the product name OncoPoint. The usual dosage can be found in the package insert. It is advised to keep the medicine in a tightly sealed container and stored in a cool, dry place between 15°-30°C (59°-86°F). The product's National Drug Code (NDC) is 68001-491-04, and it comes in a pack of 30 tablets.*

FDA Label Image

Imatinib-structure (Imatinib Structure)

FDA Label Image

100mg Label (Spl Imatinib 100 mg)

This is a medication manufactured by Sun Pharmaceutical Industries Ltd. Each tablet contains 100mg of Imatinib Mesylate. It is dispensed in a USP controlled room and should be kept in a tight container. The recommended dosage can be found in the package insert. The drug should be kept away from children.*

FDA Label Image

Spl-imatinib-fig1 (Spl Imatinib Fig1)

This is a statistical report on clinical trial data comparing the progression of patients on Imatinib Mesylate arm and patients on 1FN+Ara-C arm. The report shows the number of patients with progression and those censored at discontinuation or last follow-up. It also shows a Hazard Ratio of 0.378 with a 95% Confidence Interval of 0.291 and 0.493 and a Log-rank Test P value of less than 0.0001. The last column shows the duration in months since randomization.*

FDA Label Image

Spl-imatinib-fig2 (Spl Imatinib Fig2)

This is a statistical analysis of patients treated with Imatinib Mesylate with or without FN+Ara-C for progression to AP or BC. The table shows the number of patients, with progression and those censored, along with the calculated hazard ratio and Log-rank test results. The study analyzes patients over time, measured in months since randomization.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.